Shands HealthCare to Pay $26M to Settle False Claims Allegations
Federal prosecutors say improper Medicare billing at six Florida hospitals operated by Shands ran from 2003 through 2008. Shands makes no admission of liability, but will pay a total of approximately $26 million plus interest.
Shands HealthCare will pay $26 million to settle whistleblower allegations that six of its Florida hospitals knowingly billed the government for inpatient procedures that should have been outpatient services, federal prosecutors said Monday.
"The Department of Justice is committed to ensuring that Medicare funds are expended appropriately, based on the medical needs of patients rather than the desire of healthcare providers to maximize profits," Stuart F. Delery, assistant attorney general for the Department of Justice's Civil Division, said in prepared remarks. "Hospitals participating in Medicare must bill for their services accurately and honestly."
The six Florida hospitals were named as defendants in a whistleblower lawsuit brought under the False Claims Act. Prosecutors said an audit showed that the improper billing at the six hospitals ran from 2003 through 2008 and that Shands officials knowingly submitted the improper claims to Medicare, Medicaid, and TRICARE.
The six Florida hospitals are: Shands at Jacksonville; Shands at Gainesville, also known as Shands at the University of Florida; Shands Alachua General Hospital; Shands at Lakeshore; Shands Starke and Shands Live Oak. Specifics details of the billing scheme were not provided in a media release issued by prosecutors.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening